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Abstract
Background: Hypertension and proteinuria are critically involved in the progression of chronic kidney disease.
Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients.
Aldosterone excess is a risk factor for progression of kidney disease. Hyperkalaemia is a concern with the use
of mineralocorticoid receptor antagonists. We aimed to determine whether the renal protective benefits of
mineralocorticoid antagonists outweigh the risk of hyperkalaemia associated with this treatment in patients
with chronic kidney disease.
Methods: We conducted a meta-analysis investigating renoprotective effects and risk of hyperkalaemia in
trials of mineralocorticoid receptor antagonists in chronic kidney disease. Trials were identified from MEDLINE
(1966–2014), EMBASE (1947–2014) and the Cochrane Clinical Trials Database. Unpublished summary data were
obtained from investigators. We included randomised controlled trials, and the first period of randomised
cross over trials lasting ≥4 weeks in adults.
Results: Nineteen trials (21 study groups, 1 646 patients) were included. In random effects meta-analysis,
addition of mineralocorticoid receptor antagonists to renin angiotensin system inhibition resulted in a reduction from
baseline in systolic blood pressure (−5.7 [−9.0, −2.3] mmHg), diastolic blood pressure (−1.7 [−3.4, −0.1] mmHg) and
glomerular filtration rate (−3.2 [−5.4, −1.0] mL/min/1.73 m2). Mineralocorticoid receptor antagonism reduced weighted
mean protein/albumin excretion by 38.7 % but with a threefold higher relative risk of withdrawing from the trial due to
hyperkalaemia (3.21, [1.19, 8.71]). Death, cardiovascular events and hard renal end points were not reported in sufficient
numbers to analyse.
Conclusions: Mineralocorticoid receptor antagonism reduces blood pressure and urinary protein/albumin excretion
with a quantifiable risk of hyperkalaemia above predefined study upper limit.
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Background
Chronic kidney disease (CKD) is associated with risk of
premature cardiovascular (CV) disease and death [1–6].
Hypertension (HTN) is the major modifiable risk factor
for CKD progression and is associated with development
of left ventricular hypertrophy (LVH) and proteinuria,
both predictors of CV mortality [3, 7]. In CKD patients
with proteinuria and/or HTN renin angiotensin system
(RAS) inhibitors are commonly prescribed as these
agents have been shown to reduce proteinuria and delay
CKD progression through a combination of BP dependent
and independent mechanisms. Despite this, patients still
progress to end stage renal disease (ESRD) or die from
CV events [8–14].
There is renewed interest in aldosterone as a medi-
ator of CV and renal disease, beyond its BP effect
resulting in an enthusiasm for using mineralocorticoid
receptor antagonists (MRA) to minimised proteinuria
and delay CKD progression. A 2009 meta-analysis,
updated in 2014 demonstrated that addition of MRA
to RAS blockade reduced BP and proteinuria in CKD
[15, 16]. The beneficial effects on outcomes were con-
founded by increased risk of hyperkalaemia, a factor
limiting MRA prescribing in CKD [17–19]. Similar
findings were described in a more recent meta-
analysis on the cardiovascular actions of MRAs in
CKD [20]. However, the conclusions of these analyses
are drawn from mainly published proteinuria data
only, derived by consolidating disparate urinary pro-
tein excretion measures used in different trials (variably
reported as protein or albumin excretion in spot
samples or 24 h collections). Furthermore, in some
studies in these meta-analyses, the MRA effect is
impossible to dissociate from that of additional anti-
hypertensives co-administered with MRA in the inter-
vention arm.
In the past 6 years several studies of effects of se-
lective and non-selective MRAs in CKD have been
published [21–34]. We performed an updated meta-
analysis of this treatment strategy using summarised
unpublished data where possible, as well as including
data from 3 studies which were not considered in the
previous publication [28, 30, 34]. This is particularly
relevant as one of these studies focussed on patients
with CKD stage 3–4 [30] an area where evidence for
use of this strategy is lacking, and also because the
resultant number of participants included exceeds that
of the previous publications. We focused on change
in urinary protein/albumin excretion, progression of
CKD and risk of hyperkalaemia whilst additionally
collecting hard clinical endpoints where these data
were available. Our aim was to determine whether
renoprotective benefits of MRAs outweigh risk of
hyperkalaemia associated with this treatment.
Methods
Literature search was performed independently by two
authors (GC, AT) using PubMed (1966 - 1st Dec 2014),
EMBASE (1947 - 1st Dec 2014) and the Cochrane
Clinical Trials Database. Search strategy is shown in
Appendix 1 (see Additional file 1).
Trial type
We analysed randomised controlled trials in humans
published in English of both selective and non-selective
MRAs performed in CKD stage 1–5 where MRA was
compared to placebo or open label trials where MRA
was additional therapy compared to the non-MRA arm.
Trials were eligible if MRA was used alone or combined
with ACE-I alone, ARB alone, or both ACE-I and ARB,
performed in CKD patients or for prevention of CKD
progression. The first period of randomised crossover
trials was also considered eligible. Trials directly com-
paring MRA to other antihypertensive agents were
excluded.
Participants
Trials enrolling patients with CKD stages 1–5 not re-
quiring RRT, with albuminuria or proteinuria were
included [11]. Our search included haemodialysis, peri-
toneal dialysis and renal transplantation ensure all ap-
propriate trials were identified but RRT studies were
excluded from the main analysis to minimise the
confounding effect of dialysis on blood pressure and
potassium.
Interventions
Trials using selective and non-selective MRAs with pla-
cebo, ACE-I, ARB or both were included. Minimum trial
duration was 4 weeks.
Outcome measures
Analysis plan included effects of MRAs on the following
measures:
a) End of treatment urinary albumin or protein
excretion (24-h proteinuria or albuminuria,
or urinary protein ratio or albumin creatinine
ratio)
b) End of treatment renal function: serum creatinine
(μmol/L); eGFR (ml/min/1.73 m2); creatinine
clearance (ml/min); doubling of serum creatinine;
need for RRT. When several measures of kidney
function were available this was meta-analysed
following the hierarchy- isotopic GFR, creatinine
clearance from 24 h urine collection, eGFR (MDRD
or CKD-EPI formulae), formula estimated creatinine
clearance (Cockcroft-Gault)
c) End of treatment SBP and DBP (mmHg)
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d) Hyperkalaemia (serum potassium above trial
protocol limit)
e) Death, need for RRT, cardiovascular events.
Data collection
The search strategy in Additional file 1: Appendix 1
identified titles and abstracts. Both reviewers assessed
titles and abstracts independently, discarding those
not meeting inclusion criteria. Full texts of remaining
trials were independently assessed. A third author
(PM) settled discrepancies. Data extraction was per-
formed using specific extraction forms (Appendix 2,
see Additional file 1). Original authors were contacted
tor further information.
Assessment of risk of bias
Two independent reviewers (GC, AT) assessed trial
quality using the Cochrane Collaboration risk of bias as-
sessment tool [35]. Items assessed were: adequate se-
quence generation; allocation concealment; blinding of
participants, trial personnel and outcome assessors;
reporting of incomplete outcome data; suggestion of se-
lective outcome reporting and intention to treat analysis
(Additional file 1: Table S1).
Statistical analysis
Random effects meta-analysis was performed for con-
tinuous and categorical outcomes. For continuous out-
comes, weighted mean differences were performed using
two approaches: in analyses of continuous data, final
visit results were compared for treatment and control
arms after verifying by meta-analysis that baseline data
for the relevant outcome were no different between trial
arms; second, where sufficient data were available,
change in weighted mean difference from baseline to
final visit was calculated by meta-analysis. For categor-
ical outcomes, we calculated risk ratios (RRs) as ratio of
cumulative incidence and 95 % CIs from available data
for trial participants at baseline and for those developing
the outcome of interest. Random effects models were
used as preferable approach to manage between-trial
heterogeneity introduced by analysing differing trial pop-
ulations. As standard deviations were unavailable for all
measures of change in albuminuria and proteinuria, per-
centage change was analysed using weighted means and
weighted standard deviations across trials in exploratory
analyses. Statistical heterogeneity across studies was
quantified using I2 statistics, providing measure of pro-
portion of overall variation attributable to between-trial
heterogeneity, with p < 0.10 considered significant. We
assessed publication bias with funnel plots and Egger
tests, for the most commonly reported outcome -
SBP. Analyses were conducted using Stata version 13
(StataCorp, College Station, Texas).
Results
Literature search and trial characteristics
Search results
Search of PubMed, EMBASE and the Cochrane database
identified 299 citations. 243 were excluded (overlapping
searches; non-randomised trials; trials evaluating inter-
ventions not included in this review) (Fig. 1). Full text
assessment of 56 articles resulted in selection of 19 eli-
gible trials including 1646 patients [22–31, 34, 36–43],
more than were included in the previously published
meta-analyses [15, 16, 20]. Authors were contacted for
unpublished data; we obtained supplemental sum-
marised results for ten trials [23, 26–30, 39, 40, 42, 43].
These were whole group mean and standard deviations
pre- and post- intervention for the outcomes of interest,
allowing a more complete and precise analysis.
One trial compared ACE-I and ARB (or placebo) and
Spironolactone (or placebo), (four groups in total) [37]
and another compared two doses of Eplerenone against
placebo, (three groups in total) [38]. All comparable
arms of both trials were included for analysis. Therefore,
19 trials of 21 study groups were included for analysis.
Fourteen trials (889 patients) compared Spironolactone
plus ACE-I or ARB with ACE-I or ARB alone; and 5 tri-
als (757 patients) compared Eplerenone plus ACE-I or
ARB to ACE-I or ARB alone. One trial focused on triple
RAS blockade vs dual RAS blockade [41]. We did not
identify any trials comparing MRA to placebo in the
absence of ACE-I/ARB treatment.
Trial characteristics
Included were five randomised placebo controlled trials,
seven randomised controlled trials (treatment compared
to standard care) and seven randomised crossover trials.
Six trials included patients with non-diabetic CKD, eight
trials focused on diabetic nephropathy, 3 included both
diabetic and non-diabetic CKD and 2 included patients
with CKD and HTN.
Study duration was between 8 and 52 weeks. Sample
size was small (n = 18 to 359). No trials were powered to
measure mortality or long-term renal outcomes. Dose of
Spironolactone was 25 mg/day in most trials, while two
trials used 25–50 mg [24, 42]. Eplerenone dose ranged
from 25 to 100 mg.
The primary endpoint in the majority of trials was
change in urinary protein/albumin excretion, although
there was significant heterogeneity in measures used.
Trials reported change in urine protein:creatinine ratio
(PCR); albumin:creatinine ratio (ACR) or 24-h urine
protein/albumin excretion. In three trials change in
protein/albumin excretion was a secondary outcome
measure where BP, pulse wave velocity and left ven-
tricular mass index (LVMI) respectively were primary
endpoints [23, 24, 30].
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In trials reporting estimated glomerular filtration rate
(eGFR) calculation method included Modification of
Diet in Renal Disease (MDRD); Cockcroft Gault cre-
atinine clearance (CrCl) and Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) tools. In three
trials GFR was measured by 51Cr-EDTA [26, 39, 40].
Characteristics of participants and interventions of in-
cluded trials are listed in Table 1.
Trial quality
Trial quality assessed using the Cochrane Collaboration
tool was variable (Additional file 1: Table S1). Sequence
generation was adequately described in 9 (50 %) trials.
Allocation concealment was adequate in 8 (44 %) trials.
Participants and investigators were blinded in 12 (67 %)
trials and intention to treat analysis was performed in 2
(11 %) trials. Dropouts were adequately accounted for in
16 (84 %) trials and did not differ between treatment
and control groups.
Trial outcomes
Baseline data from included studies is shown in Additional
file 1: Table S2. Meta-analysis of baseline data for all
outcomes of interest showed these were balanced,
confirming that end-of-trial meta-analysis was appro-
priate (Additional file 1: Table S3).
Effect of treatment on blood pressure
There was a significant change in systolic blood pressure
(SBP) at final visit (−5.7 mmHg) and in the nine trials
where change from baseline (−3.3 mmHg) was available,
with addition of MRA to ACE-I and/or ARB in compari-
son to ACE-I and/or ARB alone (Fig. 2a). Addition of
MRA to ACE-I and/or ARB also led to a significant
change in end of trial diastolic blood pressure (DBP)
(−1.7 mmHg) and change from baseline to final visit
(−2.8 mmHg) in comparison to ACE-I and/or ARB alone
(Table 2).
Effect of treatment on renal excretory function
There was a small, non-significant increase in end-of-
trial serum creatinine (3.8 μmol/L) with addition of
MRA to ACE-I and/or ARB compared to ACE-I and/or
ARB alone (Table 3). Addition of MRA to ACE-I and/or
ARB led to similar change in eGFR (−2.7 mL/min/
1.73 m2) and CrCl (−2.5 mL/min) compared to ACE-I
and/or ARB alone with little heterogeneity between in-
cluded study groups respectively (I2 = 0 %, P = 0.696 and
I2 = 0 %, P = 0.727) (Fig. 2b).
Effect of treatment on urinary albumin/protein excretion
In trials reporting ACR, there was a non-significant
change (−10.91 mg/mmol creatinine) with addition of
Fig. 1 Study flow chart
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Table 1 Summary of populations and interventions in included studies. Data are mean ± SD or median (IQR)
Study Kidney disease No. of patients
included
Intervention group Control group Co-intervention Study
duration
Baseline eGFR
(ml/min/1.73 m2)
Endpoints
Abolghasmi 2011 [24] CKD with resistant
hypertension
41 Spironolactone
25–50 mg
Placebo multi-drug regime
including ACE-I+/−ARB
12 weeks Not available BP, potassium, creatinine,
urinary sodium
Ando 2014 [28] CKD with hypertension 314 Eplerenone
50 mg
Placebo ACE-I+/−ARB of at least
8 weeks duration
1 year Treatment 67.7 ± 14.3
Control 68.6 ± 13.6
UACR, creatinine, eGFR,
urinary L-FABP, 24 h
urinary sodium, incidence
of cerebrovascular and
cardiovascular events
Bianchi 2006 [36] Non-diabetic CKD
(idiopathic GN)
165 Spironolactone
25 mg
ACE-I+/−ARB ACE-I+/−ARB 1 year Treatment 62.4 ± 21.9
Control 62.2 ± 19.0
24 h urinary protein, BP,
creatinine, eGFR potassium
Boesby 2011 [29]
(XO)
Non-diabetic CKD 40 Eplerenone
25–50 mg
multi-drug regime
including ACE-I+/−ARB
multi-drug regime
including ACE-I+/−ARB
8 weeks 59 ± 26 24 h urinary albumin, BP,
potassium, creatinine
clearance
Boesby 2013 [30] Diabetic and
non-diabetic CKD
26 Eplerenone
25–50 mg
ACE-I+/−ARB ACE-I+/−ARB 24 weeks 36 ± 10 cfPWV, AIx, AASI, 24 h
urinary albumin
Chrysostomou 2006a
[37]
Diabetic and
non-diabetic CKD
41 Spironolactone
25 mg
Placebo as ARB;
Placebo as
Spironolactone
ACE-I alone; ACE-I +
ARB
3 months Not available 24 h urinary protein, BP,
creatinine, creatinine
clearance, potassium
Edwards 2009 [23] Non-diabetic CKD with
no renovascular
diagnosis
112 Spironolactone
25 mg
Placebo ACE-I/ARB 36 weeks Treatment 49 ± 12
Control 53 ± 11
LVMI, cfPWV, aortic
distensibility, AIx, BP
Epstein 2006+ [38] Diabetic nephropathy 359 Eplerenone
50 mg or 100 mg
Placebo ACE-I 12 weeks ACE ± EPL 50
73 (62.1–83.6)
ACE ± EPL 100
75 (62.8–85.9)
Control
74 (60.5–82.2)
UACR, potassium, BP, eGFR
Guney 2009 [25] Non-diabetic CKD 24 Spironolactone
25 mg
ACE-I+/−ARB ACE-I+/−ARB 6 months Treatment 63.0 ± 22.71
Control 56.3 ± 35.6
UPCR, urinary TGF-β1,
eGFR, creatinine,
potassium, BP, aldosterone
Mehdi 2009 [22] Diabetic nephropathy 81 Spironolactone
25 mg
Placebo or ARB ACE-I 48 weeks Not available UACR, BP, creatinine
clearance, potassium
Nielsen 2012 [26]
(XO)
Diabetes with
microalbuminuria
21 Spironolactone
25 mg
Placebo ACE-I/ARB 60 days Not available 24 h urinary albumin, BP,
GFR, urinary L-FABP,
urinary NGAL, urinary
KIM-1
Rossing 2005 [39]
(XO)
Diabetic nephropathy 20 Spironolactone
25 mg
Placebo ACE-I+/−ARB 8 weeks Not available 24 h urinary albumin,
BP, GFR
Saklayen 2008 [43]
(XO)
Diabetic nephropathy 24 Spironolactone
25–50 mg
Placebo ACE-I/ARB 3 months Treatment 61.9 ± 23.4
Control 54.4 ± 20.1
BP, creatinine, potassium,
UPCR
Schjoedt 2005 [40]
(XO)
Diabetic nephropathy 20 Spironolactone
25 mg
Placebo ACE-I+/−ARB 2 months Not available 24 h urinary albumin,
BP, GFR
C
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Table 1 Summary of populations and interventions in included studies. Data are mean ± SD or median (IQR) (Continued)
Tylicki 2008 [41]
(XO)
Non-diabetic CKD 18 Spironolactone
25 mg
ACE-I + ARB ACE-I + ARB 8 weeks 107.8 (93–140.9) 24 h urinary protein, BP,
creatinine, potassium,
PRA, urinary NAG, urinary
PIIINP
Tylicki 2012 [31]
(XO)
Non-diabetic CKD 18 Eplerenone
50 mg
ARB + Aliskiren ARB 8 weeks Not available UACR, BP, creatinine
clearance, potassium
van den Meiracker
2006 [42]
Diabetic nephropathy 53 Spironolactone
25–50 mg
Placebo ACE-I/ARB 1 year Treatment 93.1 ± 45
Control 66.3 ± 35.1
24 h urinary protein, BP,
creatinine, eGFR, potassium
Wang 2013 [34] Diabetic and
non-diabetic CKD
208 Spironolactone
20 mg
multi-drug regime
including ACE-I+/−ARB
multi-drug regime
including ACE-I+/−ARB
16 weeks Treatment 65.8 ± 22.2
Control 66.5 ± 24.3
24 h urinary protein,
creatinine, potassium,
eGFR, BP, aldosterone
Ziaee 2013 [27] Diabetes with
microalbuminuria
60 Spironolactone
25 mg
ACE-I ACE-I 12 weeks Treatment 79.8 ± 18
Control 82.5 ± 19.1
UACR, BP, potassium, eGFR
UACR urine albumin:creatinine ratio, UPCR urine protein:creatinine ratio, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CKD chronic kidney disease, NG glomerulonephritis, L-FABP
liver-type fatty acid binding protein, XO crossover study design, cfPWV carotid-femoral pulse wave velocity, AIx augmentation index, AASI ambulatory arterial stiffness index, LVMI left ventricular mass index, TGF-β1
transforming growth factor-β1, NGAL neutrophil gelatinase associated lipocalin, KIM-1 kidney injury molecule-1, PRA plasma renin activity, NAG n-acetyl-β-D-glucosaminidase, PIIINP amino-terminal propeptide of type III
procollagen, athis study had 4 arms +this study had 3 arms
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 40.0%, p = 0.101)
Boesby (2013)
Saklayen
Van der Meiracker
Rossing
TRIAL
Schojedt
Ziaee
Nielsen
Boesby (2011)
Edwards
-2
-12.04
-7.1
-13
SBP 
MRA
-4.67
-10
1.56
-5
-11
3
22.6
14.2
17.3
SD
22.4
8.1
9.9
8
12
-2
-5.7
-3.5
-2.73
SBP 
Control
1.25
-5.97
3.65
-1
-5
3
28.1
14.4
17.1
SD
14
6.9
11.7
11
14
-3.30 (-5.56, -1.04)
0.00 (-1.65, 1.65)
-6.34 (-20.78, 8.10)
-3.60 (-11.33, 4.13)
-10.27 (-20.93, 0.39)
WMD (95% CI)
-5.92 (-17.50, 5.66)
-4.03 (-7.85, -0.21)
-2.09 (-8.65, 4.47)
-4.00 (-8.22, 0.22)
-6.00 (-10.83, -1.17)
100.00
28.63
2.29
6.84
3.98
Weight %
3.43
17.19
8.79
15.55
13.31
0-10-20 2010
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.790)
Mehdi
Wang
Saklayen
Guney
Nielsen
Schojedt
Rossing
Boesby (2011)
Chrystosostomou A
TRIAL
Ando
Bianchi
Van der Meiracker
Tylicki (2012)
Edwards
Chrystosostomou B
Ziaee
Boesby (2013)
51.6
64.1
53.9
58.4
68.8
81.3
71.4
58
56.5
GFR 
MRA
64.1
58.6
75.2
97.3
46
54.3
75.6
50
37
31
24
24
31
26
28
25
30
SD
17
24
37
34
14
17
16
19
64.3
63.5
55.3
58.7
75
84.7
74
59
67.4
GFR 
control
68
56.4
59.8
97.9
52
84.5
79.6
54
45
37
23
39
30
29
26
25
43
SD
17
21
35
34
12
61
17
28
-3.15 (-5.36, -0.95)
-12.70 (-34.58, 9.18)
0.60 (-8.62, 9.82)
-1.32 (-14.42, 11.78)
-0.32 (-23.53, 22.89)
-6.25 (-24.83, 12.33)
-3.40 (-20.26, 13.46)
-2.60 (-19.18, 13.98)
-1.00 (-11.96, 9.96)
-10.90 (-43.09, 21.29)
WMD (95% CI)
-3.90 (-7.56, -0.24)
2.20 (-4.60, 9.00)
15.40 (-4.03, 34.83)
-0.60 (-23.05, 21.85)
-6.00 (-10.83, -1.17)
-30.20 (-69.21, 8.81)
-4.00 (-12.33, 4.33)
-4.00 (-17.18, 9.18)
100.00
1.02
5.73
2.84
0.90
1.41
1.71
1.77
4.06
0.47
36.30
10.52
1.29
0.97
20.88
0.32
7.02
2.80
Weight %
0-30 30 60-60
NOTE: Weights are from random effects analysis
Overall  (I-squared = 69.5%, p = 0.011)
Chrystosostomou  A
Ando
Mehdi
Van der Meiracker
TRIAL
Chrystosostomou B
-48.2
-17.3
-51.6
-44.2
% change 
MRA
-42
7
8
13
10
SD
9
-15.7
10.3
-24.6
-14.3
% change
control
-1.4
10
7
21
7
SD
8
-31.03 (-35.34, -26.72)
-32.50 (-39.89, -25.11)
-27.60 (-29.34, -25.86)
-27.00 (-36.08, -17.92)
-29.90 (-34.72, -25.08)
WMD (95% CI)
-40.60 (-47.91, -33.29)
100.00
16.52
30.58
13.25
22.94
Weight %
16.71
0-50 -25 25 50
a
b
c
Fig. 2 (See legend on next page.)
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MRA to ACE-I and/or ARB (Table 3). Where data for
end-of-trial 24-h urinary albumin excretion were avail-
able, there was significant change associated with MRA
in addition to ACE-I and/or ARB (−332.9 mg/24 h). This
was confirmed in the 3 trials reporting change from
baseline albumin excretion, (−292.23 [−422.2, −162.3]
mg/24 h). In trials reporting PCR, MRA added to ACE-I
and/or ARB led to significant change in end-of-trial
values (−0.91 g/g creatinine) compared with ACE-I and/
or ARB alone (Table 3). Change in 24-h urine protein
from baseline to end-of-trial was available from two tri-
als and showed a trend towards reduction (−0.41 g/24 h)
(Table 3) [34, 41].
Analysis of absolute values may be misleading with
non-parametric data; therefore we assessed relative
change from baseline in urinary protein/albumin excre-
tion where these data were available. There was a signifi-
cant reduction in urinary protein/albumin excretion
with MRA analysed using the 5 trials which reported
percentage change from baseline and where SD were
available (Fig. 2c); and also when analysed as percentage
change in any measure of urinary protein/albumin ex-
cretion. Using difference in means analysis in order
to include data from all 19 trials, addition of MRA to
ACE-I and/or ARB led to weighted mean reduction of
38.7 % (weighted SD 21.5 %) in any measure of protein/
albumin excretion. The pattern of association between
reduction in SBP and percentage reduction in urinary
protein/albumin excretion is shown in Additional file 1:
Figure S1.
Effect of treatment on potassium
Addition of MRA to ACE-I and/or ARB led to a
moderate increase from baseline potassium compared
to ACE-I and/or ARB alone both at end-of-trial visit
(0.19 mmol/L [95 % CI 0.07–0.31]; 16 trials; n = 1356;
I2 = 83.8 %) and analysed as change from baseline to
end-of-trial (0.19 mmol/L [95 % CI 0.12–0.27]; 8 trials;
n = 478; I2 = 0 %. Baseline serum creatinine had no im-
pact on difference in end of trial potassium (p = 0.15) or
risk of hyperkalaemia (p = 0.21).
MRA was associated with threefold increased risk of
hyperkalaemia above the predefined trial limit (Fig. 3a).
Diabetic CKD patients were not at greater risk of devel-
oping hyperkalaemia than patients with CKD of alterna-
tive aetiology (p = 0.38) (Fig. 3b). Number needed to
harm for 1 year of treatment, calculated from trials
reporting at least one case of hyperkalaemia, was 10
(95 % CI 5–27). Relative risk of being withdrawn
from active treatment due to hyperkalaemia was increased
(RR 3.21, 95 % CI 1.19, 8.71), equating to number needed
to harm over 1 year of 23 (95 % CI 7–267) in trials where
at least one patient stopped therapy.
Hard clinical endpoints
Included studies were not adequately powered for ana-
lysis of hard clinical outcomes. No studies reported par-
ticipants commencing RRT during the course of the
trial. One study reported a participant death (cause un-
known) in the treatment group [28] but there were no
deaths reported from the remaining 18 studies. Cardio-
vascular morbidity was reported by two groups [22, 28].
In one study, one patient in the treatment group devel-
oped atrial fibrillation and one in the control group
suffered a cerebrovascular accident (CVA) [28]. Mehdi
et al. reported occurrence of two CVA, two hospitalisa-
tions for heart failure, one myocardial infarction and one
coronary artery bypass graft in the treatment group;
whilst one subject in the placebo group suffered a CVA
(Additional file 1: Table S4) [22]. A significant reduction
in mortality with addition of MRA was seen in dialysis
studies (Additional file 1: Figure S2).
(See figure on previous page.)
Fig. 2 a Change in systolic blood pressure from baseline with addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone.
For participant numbers see Table 1. b Effect of the addition of MRA to ACE-I and/or ARB compared with ACE-I and/or ARB alone on
end of treatment renal excretory function. For participant numbers see Table 1. c Percentage change from baseline of any measure of
urinary protein/albumin excretion with the addition of MRA to ACE-I and/or ARB compared with ACE-I and/or ARB alone. For participant
numbers see Table 1
Table 2 Effect of addition of MRA on final visit blood pressure
Variable Measurement No. of study
groups
No. patients in
intervention
No. patients in
placebo/control
Effect size (95 % CI) I2 (p value)
Systolic BP (mmHg) Change from baseline 9 260 266 −3.30 (−5.56, −1.04) 40.0 % (0.101)
Final visit 16 666 659 −5.69 (−9.04, −2.34) 81.8 % (0.000)
Diastolic BP (mmHg) Change from baseline 9 260 266 −2.84 (−3.35, −2.33) 0.0 % (0.799)
Final visit 16 666 659 −1.73 (−3.37, −0.10) 68.3 % (0.000)
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Heterogeneity
Heterogeneity was considerable for analyses of most out-
comes (SBP, end-of-trial DBP, serum creatinine, urinary
ACR and PCR, end-of-trial 24 h urinary albumin). How-
ever, heterogeneity was limited for other outcomes
(Tables 2 and 3).
Publication bias
There was some suggestion of publication bias for
SBP, evidenced by funnel plot (Fig. 4) and Egger test
(p = 0.08), but not for end of study GFR or hyperka-
laemia (Additional file 1: Figures S3 and S4).
Discussion
The beneficial impact of RAS blockade with ACE-I and
ARB in both diabetic and non-diabetic CKD is well
established [8–10, 13]. However, studies of combination
therapy suggest harm in particular because of increased
risk of hyperkalaemia and/or need for dialysis, and this
treatment strategy is therefore generally avoided [44, 45].
Accumulating evidence suggests an independent role for
aldosterone in development and progression of CV and
renal disease [46–49]. Recent trials included in this ana-
lysis demonstrate beneficial effects on BP and urinary
protein excretion in CKD with addition of MRA to
ACE-I and ARB therapy. These benefits may however be
offset by increased risk of hyperkalaemia or decline in
renal function.
This meta-analysis confirms that MRA use in combin-
ation with ACE-I and/or ARB is associated with signifi-
cant reductions in BP and end-of-treatment protein/
albumin excretion, while conferring a small and quantifi-
able increased risk of hyperkalaemia. These findings
are in keeping with previous published meta-analyses
[15, 16, 20]. By using additional unpublished summary
results from a number of authors, we ensure that our pro-
tein/albumin excretion data are more comprehensive and
hence more accurate. Through excluding studies where
additional therapy was combined with MRA, we are
confident that we report purely the effect of MRA on out-
comes. Furthermore, we report clinically relevant risk of
hyperkalaemia as relative risk and number needed to
harm.
Many studies show strong independent associations
between albuminuria and development of ESRD, trans-
lating into its widespread use as a surrogate outcome in
CKD trials. A recent meta-analysis of over 78 000 patients
confirmed that 30 % reduction in albuminuria confers
23.7 % reduction in risk of progression to ESRD, irrespect-
ive of drug class [50]. We demonstrate that addition of
MRA to ACE-I and/or ARB achieves 40 % reduction in
measures of protein/albumin excretion. This should trans-
late to greater benefits in reduction in risk of ESRD and
potentially in CV disease [51]. It is possible that reduction
in protein/albumin excretion seen with MRA treatment is
not entirely BP dependent (Additional file 1: Figure S1).
BP independent effects of MRA on proteinuria are diffi-
cult to determine in the presence of substantial BP lower-
ing effects with MRA seen across the trials.
Follow-up period of included trials was <1 year and
mean baseline eGFR was >35 ml/min/1.73 m2 in all
studies, therefore impact of addition of MRA to RAS
blockade on longer-term renal outcomes or mortality in
the later stages of CKD cannot be evaluated. Establishing
efficacy of MRA treatment on morbidity and mortality
in CKD requires longer follow up and larger sample size.
One ongoing study may address this [52]. None of the
studies included were powered to detect differences in
hard renal end-points, CV morbidity or mortality. We
cannot draw conclusions regarding longer-term safety
and efficacy of combination MRA and/or ARB, despite
postulated CV benefits of reducing protein/albumin ex-
cretion [53]. This is in keeping with a meta-analysis pub-
lished last year [20].
Hyperkalaemia is an inherent risk associated with
using MRA combined with RAS blockers and a common
Table 3 Effect of addition of MRA on final visit renal function and urinary protein/albumin excretion
Variable Measurement No. of study
groups
No. patients in
intervention
No. patients in
placebo/control
Effect size (95 % CI) I2 (p value)
Creatinine (μmol/L) Final visit 16 601 595 3.83 (−2.14, 9.79) 50.4 % (0.011)
Creatinine Clearance (ml/min) Final visit 6 132 130 −2.51 (−7.05, 2.04) 0.0 % (0.599)
eGFR (ml/min/1.73 m2) Final visit 13 626 617 −2.71 (−4.85, −0.57) 0.0 % (0.727)
GFR (any measure) Final visit 17 692 682 −3.15 (−5.36, −0.95) 0.0 % (0.790)
Urinary ACR (mg/mmol) Final visit 7 355 351 −10.91 (−26.15, 4.32) 83.4 % (0.000)
Urinary PCR (g/g creatinine) Final visit 4 146 150 −0.91 (−1.35, −0.46) 58.4 % (0.065)
24 h urinary albumin excretion (mg/24 h) Final visit 6 151 155 −332.91 (−624.80, −41.02) 66.5 % (0.011)
Change from
baseline
3 90 94 −292.23 (−422.19, −162.27) 0.0 % (0.606)
24 h urinary protein excretion (g/24 h) Final visit 2 124 121 −0.41 (−0.90, 0.09) 77.1 % (0.037)
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Fig. 3 (See legend on next page.)
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occurrence in studies of dual RAS blockade. Data from
the ONTARGET study showed that combination ACE–I
and ARB increased risk of dialysis, doubling of creatinine
or death and combination treatment is not recom-
mended in clinical guidelines [44]. We show an average
potassium increase of 0.19 mmol/L at end of treatment
(similar to previous data [15, 16]) and three times
greater risk of hyperkalaemia in patients receiving MRA
in addition to ACE-I and/or ARB. It is essential to con-
sider that this does not necessarily equate to risk of de-
veloping clinically significant hyperkalaemia requiring
treatment, rather of developing a serum potassium level
above the predefined study upper limit, which in many
trials was 5.5–6 mmol/L. Although few patients were
withdrawn due to hyperkalaemia, many trials reported
no withdrawals and only one study reported a single in-
cidence of hyperkalaemia requiring hospital admission
for treatment. The implications of these findings are un-
clear but the small increase in potassium suggests that if
patients with high-normal baseline potassium values are
excluded from treatment, the risk of dangerous hyperka-
laemia may in fact be low. Hyperkalaemia has been asso-
ciated with risk of renal events in patients with diabetes
and nephropathy [54]. Our analysis did not demonstrate
diabetic CKD to be at greater risk of developing hyper-
kalaemia than non-diabetic CKD.
Patients prescribed MRA require regular monitoring
of potassium. Although serum potassium levels climb
with chronic dosing in dual RAS blockade, the pattern is
of early increase followed by steady state, not continuous
increase [19]. It is conceivable that benefits conferred by
40 % reduction in proteinuria outweigh the risk of small
rises in potassium. Recent data suggest that nonsteroidal
mineralocorticoid receptor antagonists may carry a re-
duced risk of side-effects, and these agents have shown
promise for reduction of albuminuria in diabetic CKD
[55]. In addition, recent literature highlights the poten-
tial for use of potassium binders in higher risk patients
[56]. As well as addressing safety, evaluation of eco-
nomic effects of increased monitoring of potassium
compared reduction in CV events or progression of
CKD is required.
Our study includes independent systematic searching,
data extraction and assessment of study quality by two
independent reviewers based on a pre-specified strategy.
In addition, many authors provided supplemental sum-
mary data thereby enabling more comprehensive ana-
lysis. Furthermore, we obtained data from 3 studies
which were not included in the previous meta-analyses
[28, 30, 34], resulting in analysis of data from a higher
total number of patients (1646 vs 1549). This meta-
analysis has several limitations. The majority of studies
(See figure on previous page.)
Fig. 3 a Relative risk of developing hyperkalaemia above the predefined study limit with the addition of MRA to ACE-I and/or ARB compared to
ACE-I and/or ARB alone. For participant numbers see Table 1. b Relative risk of developing hyperkalaemia above the predefined study limit with
the addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone based on aetiology of CKD (DM diabetes mellitus) included in trial.
For participant numbers see Table 1
Fig. 4 Funnel plot (pseudo 95 % confidence limits) demonstrating some evidence of publication bias for SBP (Egger test p = 0.08)
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included patients with CKD stages 1–3 and therefore re-
sults may not be readily transferrable to populations
with more advanced renal disease. There is a lack of
long-term follow up data on clinical endpoints such as
mortality and CKD progression. Studies included were
small and powered to detect differences in surrogate
endpoints. Seven included studies had crossover design
[26, 29, 31, 39–41, 43] and reporting of methodology
was variable. Adequate assessment of trial quality was not
possible in all cases. There was significant heterogeneity in
measurement of protein/albumin excretion. Authors re-
ported ACR, PCR, 24 h albuminuria/proteinuria or com-
binations of these. Whilst the results demonstrate a
significant reduction in protein or albumin excretion, this
highlights that standardisation of measurements would
allow consistent analysis, particularly if albuminuria (or
equivalent) is used reliably as a surrogate for progression
to ESRD [57].
Conclusion
In conclusion, in patients with CKD, with persistent pro-
teinuria despite RAS inhibition, addition of MRA repre-
sents a promising treatment strategy for reducing BP
and proteinuria with a quantifiable risk of hyperkalae-
mia. Appropriately designed larger studies with longer-
term follow up are needed to address if MRA added to
conventional RAS blockade reduces the risk of CV dis-
ease and need for RRT.
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